- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01976754
Safety Study of Dexmedetomidine in Septic Patients
The Effective Dose of Dexmedetomidine for Moderate Sedation of Adult Intubated Septic Patients in the ICU.
Study Overview
Detailed Description
Inclusion Criteria:
Age: between 18 years mechanical ventilation RASS≥2 A diagnosis of sepsis within 48 hours
Exclusion Criteria:
Cardiac disease Cardiac rhythm abnormalities liver dysfunction coma severe hypotension muscle relaxant users
Primary Outcome Measures:
Dose of dexmedetomidine
Secondary Outcome Measures:
RASS score Requirement for rescue intervention, RASS will be recorded per hour.
Study Type
Enrollment (Anticipated)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Zhejiang
-
Hangzhou, Zhejiang, China, 310000
- Zhanqin Zhang
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- intubated patients RASS≥2 A diagnosis of sepsis within 48h
Exclusion Criteria:
- Cardiac disease Cardiac rhythm abnormalities liver dysfunction coma severe hypotension muscle relaxant users
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Supportive Care
- Allocation: Randomized
- Interventional Model: Single Group Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Other: dexmedetomidine,sepsis,ED50
Intervention Name: dexmedetomidine dosage form: intravenous injection dosage:0.2-0.7μg/kg/h
frequency: 1 duration:12 hours
|
Septic patients are randomly received 1 of 6 doses( 0.2,0.3,0.4,0.5,0.6,0.7μg/kg/h)
dexmedetomidine.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
Dose of dexmedetomidine
Time Frame: 12 hours
|
12 hours
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
RASS score Requirement for rescue intervention, RASS will be recorded per hour.
Time Frame: 1 hour
|
1 hour
|
Collaborators and Investigators
Investigators
- Principal Investigator: xiangming fang, PHD, First affiliated Hospital of Zhejiang University
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Nervous System Diseases
- Neurologic Manifestations
- Neurobehavioral Manifestations
- Dyskinesias
- Psychomotor Disorders
- Psychomotor Agitation
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Central Nervous System Depressants
- Peripheral Nervous System Agents
- Analgesics
- Sensory System Agents
- Analgesics, Non-Narcotic
- Adrenergic alpha-2 Receptor Agonists
- Adrenergic alpha-Agonists
- Adrenergic Agonists
- Hypnotics and Sedatives
- Dexmedetomidine
Other Study ID Numbers
- FirstzhejiangU
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.